ARDELYX, INC. Increase (Decrease) in Accrued Liabilities
ARDELYX, INC. (ARDX) reported Increase (Decrease) in Accrued Liabilities of $22.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- ARDELYX, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $3.42M.
- ARDELYX, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $19.02M, a 136.50% increase year-over-year.
- ARDELYX, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.43M, a 56.13% increase year-over-year.
- ARDELYX, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $4.63M, a 40.23% decline year-over-year.
- ARDELYX, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $14.54M, a 31.57% decline from fiscal 2024.
- ARDELYX, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $21.25M, a 475.83% increase from fiscal 2023.
- ARDELYX, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $3.69M, a 10.80% decline from fiscal 2022.
- ARDELYX, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $4.14M, a 198.56% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.45M 10-Q · filed 2026-08-06 | $24.88M derived: sum of 3 quarters · filed 2026-08-06 | $29.51M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $19.02M 10-Q · filed 2026-04-30 | $21.46M derived: sum of 2 quarters · filed 2026-04-30 | $26.09M derived: sum of 3 quarters · filed 2026-04-30 | $25.52M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $7.07M derived: sum of 2 quarters · filed 2026-02-19 | $6.50M derived: sum of 3 quarters · filed 2026-08-06 | $14.54M 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $4.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $4.07M derived: sum of 2 quarters · filed 2026-08-06 | $12.11M 10-Q · filed 2025-10-30 | $13.67M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$563.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.48M 10-Q · filed 2026-08-06 | $9.04M derived: sum of 3 quarters · filed 2026-08-06 | $16.79M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $8.04M 10-Q · filed 2026-04-30 | $9.60M derived: sum of 2 quarters · filed 2026-04-30 | $17.35M derived: sum of 3 quarters · filed 2026-04-30 | $22.14M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $9.31M derived: sum of 2 quarters · filed 2026-02-19 | $14.10M derived: sum of 3 quarters · filed 2026-02-19 | $21.25M 10-K · filed 2026-02-19 | ||
| 2024-09-30 | $7.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $12.54M derived: sum of 2 quarters · filed 2025-10-30 | $19.70M 10-Q · filed 2025-10-30 | $16.92M derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2024-06-30 | $4.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $11.95M 10-Q · filed 2025-08-04 | $9.17M derived: sum of 3 quarters · filed 2026-02-19 | $15.53M derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2024-03-31 | $7.16M 10-Q · filed 2025-05-01 | $6.79M 10-Q · filed 2024-05-02 | $4.38M derived: sum of 2 quarters · filed 2026-02-19 | $10.74M derived: sum of 3 quarters · filed 2026-02-19 | $12.25M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2023-12-31 | -$2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.58M derived: sum of 2 quarters · filed 2026-02-19 | $5.09M derived: sum of 3 quarters · filed 2026-02-19 | $3.69M 10-K · filed 2026-02-19 | ||
| 2023-09-30 | $6.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $7.86M derived: sum of 2 quarters · filed 2024-10-31 | $6.47M 10-Q · filed 2024-10-31 | $10.98M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-06-30 | $1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $110.00K 10-Q · filed 2024-08-01 | $4.62M derived: sum of 3 quarters · filed 2025-02-20 | $3.99M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-03-31 | -$1.40M 10-Q · filed 2024-05-02 | $3.12M derived: sum of 2 quarters · filed 2025-02-20 | $2.48M derived: sum of 3 quarters · filed 2025-02-20 | $3.78M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2022-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $3.88M derived: sum of 2 quarters · filed 2025-02-20 | $5.18M derived: sum of 3 quarters · filed 2025-02-20 | $4.14M 10-K · filed 2025-02-20 | ||
| 2022-09-30 | -$634.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $666.00K derived: sum of 2 quarters · filed 2023-10-31 | -$375.00K 10-Q · filed 2023-10-31 | -$4.40M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $259.00K 10-Q · filed 2023-08-02 | -$3.77M derived: sum of 3 quarters · filed 2024-02-22 | -$962.00K derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-03-31 | -$1.04M 10-Q · filed 2023-05-03 | -$5.07M derived: sum of 2 quarters · filed 2024-02-22 | -$2.26M derived: sum of 3 quarters · filed 2024-02-22 | -$7.17M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2021-12-31 | -$4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$1.22M derived: sum of 2 quarters · filed 2024-02-22 | -$6.13M derived: sum of 3 quarters · filed 2024-02-22 | $1.39M 10-K · filed 2024-02-22 | ||
| 2021-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.11M derived: sum of 2 quarters · filed 2022-11-03 | $5.41M 10-Q · filed 2022-11-03 | $5.28M derived: sum of 4 quarters · filed 2023-03-02 | ||
| 2021-06-30 | -$4.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.61M 10-Q · filed 2022-08-04 | $2.48M derived: sum of 3 quarters · filed 2023-03-02 | $1.43M derived: sum of 4 quarters · filed 2023-03-02 | ||
| 2021-03-31 | $7.52M 10-Q · filed 2022-05-05 | $7.39M derived: sum of 2 quarters · filed 2023-03-02 | $6.34M derived: sum of 3 quarters · filed 2023-03-02 | $6.91M derived: sum of 4 quarters · filed 2023-03-02 | ||
| 2020-12-31 | -$129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$1.17M derived: sum of 2 quarters · filed 2023-03-02 | -$606.00K derived: sum of 3 quarters · filed 2023-03-02 | -$1.00M 10-K · filed 2023-03-02 | ||
| 2020-09-30 | -$1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$477.00K derived: sum of 2 quarters · filed 2021-11-12 | -$871.00K 10-Q · filed 2021-11-12 | -$3.50M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $568.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $174.00K 10-Q · filed 2021-08-13 | -$2.45M derived: sum of 3 quarters · filed 2022-02-28 | -$3.36M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | -$394.00K 10-Q · filed 2021-05-06 | -$3.02M derived: sum of 2 quarters · filed 2022-02-28 | -$3.92M derived: sum of 3 quarters · filed 2022-02-28 | -$7.31M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | -$2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$3.53M derived: sum of 2 quarters · filed 2022-02-28 | -$6.91M derived: sum of 3 quarters · filed 2022-02-28 | -$5.86M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$907.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$4.29M derived: sum of 2 quarters · filed 2020-11-05 | -$3.24M 10-Q · filed 2020-11-05 | -$479.00K derived: sum of 4 quarters · filed 2021-03-08 | ||
| 2019-06-30 | -$3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$2.33M 10-Q · filed 2020-08-06 | -$3.15M 10-Q · filed 2019-08-09 | $428.00K derived: sum of 3 quarters · filed 2021-03-08 | $1.09M derived: sum of 4 quarters · filed 2021-03-08 | |
| 2019-03-31 | $1.05M 10-Q · filed 2020-05-07 | $3.81M derived: sum of 2 quarters · filed 2021-03-08 | $4.47M derived: sum of 3 quarters · filed 2021-03-08 | $4.35M derived: sum of 4 quarters · filed 2021-03-08 | ||
| 2018-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $3.42M derived: sum of 2 quarters · filed 2021-03-08 | $3.30M derived: sum of 3 quarters · filed 2021-03-08 | $1.35M 10-K · filed 2021-03-08 | ||
| 2018-09-30 | $659.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $540.00K derived: sum of 2 quarters · filed 2019-11-06 | -$1.41M 10-Q · filed 2019-11-06 | -$2.00M derived: sum of 4 quarters · filed 2020-03-06 | ||
| 2018-06-30 | -$119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$2.06M 10-Q · filed 2019-08-09 | -$2.66M derived: sum of 3 quarters · filed 2020-03-06 | |||
| 2018-03-31 | -$1.95M 10-Q · filed 2019-05-07 | -$2.54M derived: sum of 2 quarters · filed 2020-03-06 | ||||
| 2017-12-31 | -$594.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $245.00K 10-K · filed 2020-03-06 | ||||
| 2017-09-30 | $839.00K 10-Q · filed 2018-11-07 | |||||
| 2016-12-31 | $8.28M 10-K · filed 2019-03-06 | |||||
| 2015-12-31 | $2.00M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |